Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
abbreviated, accretion, allAzaSiteproduct, AmerisourceBergen, ancillary, ANDA, andAzaSite, andElestatare, andElestatdid, andIquix, andOmnarisTM, andPatadayTM, andProlacriaare, andProlacriafor, andTobraDex, appellate, argued, barred, bear, bitter, bothRestasisandElestat, bribery, broker, buyer, Catalent, chamber, characterize, characterized, Circuit, commercializeAzaSitewill, conclusion, consignment, Cosmetic, creation, database, debit, deducted, Deduction, deferredAzaSite, deliverAzaSite, description, destruction, devaluation, differentiateAzaSiterelative, dismissed, dossier, Elestatin, Elestaton, Eliason, embedded, essentially, exceptAzaSite, expiredAzaSite, feasible, feature, FIFO, fluorescein, forAzaSiteand, forPatanase, forRestasisandElestat, hand, inElestatcoverage, intangible, itchy, IX, jonathan, labor, launchedAzaSite, launchedAzaSitein, leff, lid, logistic, losing, lt, Magistrate, majeure, manufactureAzaSite, marketingAzaSiteandElestat, matching, McKesson, Meda, negligence, newly, nonrefundable, Nycomed, ofAzaSitein, ofAzaSitewill, ofElestatwill, ofRestasisand, ofRestasisandElestat, older, omission, opposition, ORA, ourAzaSite, ourElestat, ourProlacriadevelopment, outweigh, overhead, overstocking, owner, par, perspective, persuasive, physical, plain, predominately, prejudice, prepaid, prepayment, Prolacriafor, promoteAzaSite, promotingAzaSite, promotingElestatto, QT, question, ratio, reconciliation, recurring, reducedAzaSite, referencing, reply, reserve, reserved, Restasisand, RestasisandElestat, restructure, retail, retired, Retirement, revert, reviewAzaSite, roll, score, sector, seizure, sellAzaSite, seller, sellsAzaSite, slight, Standstill, strongly, studyingProlacria, supportAzaSite, suspension, symptom, taste, thatAzaSite, theft, toAzaSitein, toProlacriausing, toRestasisandElestat, uncollectible, undergone, unexpectedly, unmarketable, unreimbursed, vanilla, vast, waive, Warburg, whichRestasisandElestat, wholesaler, wholesaling, withAzaSite, withAzaSiteincludeVigamox, withRestasisandElestat
Removed:
accident, accidental, acid, allocation, amounting, apply, arranging, assumption, AstraZeneca, Barry, binding, biostatistical, cardiovascular, Chairman, chloride, Choshi, CIC, conference, contamination, corneal, death, diagnosed, disability, disagreement, disposal, ecabet, edema, exceeded, excluded, filled, filling, Fujisawa, generating, GlaxoSmithKline, healing, hydrochloric, hydrochloride, hydroxide, initiating, injection, injury, institution, insure, intense, involuntarily, IPO, ISTA, knowledgeable, liable, lump, MedPointe, offering, olopatadine, Otsuka, packaged, packing, paragraph, parallel, participant, Pea, pharmacopeial, platelet, pollutant, pool, proportionate, realizing, rebamipide, Recalling, regional, registering, regular, relying, removal, rescinding, retinal, reversible, rimexolone, Senju, small, sodium, specialty, team, thirty, twelve, umbrella, undergo, undergoing, underwriter, universe, unpartnered, validation, waste, weekly, wound
Filing tables
Filing exhibits
- 10-K Annual report
- 10.60 Clinical Services Agreement
- 23.1 Consent of Pricewaterhousecoopers
- 31.1 Certification of the CEO Pursuant to the Sec Act of 1934
- 31.2 Certification of the CFO Pursuant to the Sec Act of 1934
- 32.1 Certification of the CEO Pursuant to Section 906, Sarbanes-oxley Act of 2002
- 32.2 Certification of the CFO Pursuant to Section 906, Sarbanes-oxley Act of 2002
Related press release
ISPH similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-147733, 333-141169, and 333-137733) and Form S-8 (Nos. 333-56360, 333-130496 and 333-148185) of Inspire Pharmaceuticals, Inc. of our report dated March 14, 2008 relating to the financial statements, financial statement schedule and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Raleigh, North Carolina
March 14, 2008